A biosimilars boom is expected and both biopharma and contract manufacturers want to be positioned to capture a piece of the market. ISR’s Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices (4th Edition) goes into depth on one of the most important aspects of biosimilars: manufacturing. Manufacturing these complex products in a cost efficient manner will be a critical component to successfully commercializing biosimilars and the anticipated boom. Outsourced manufacturing decision-makers share their perspectives on selling and manufacturing biosimilars, how much biosimilar manufacturing is expected to be outsourced, comfort levels in outsourcing to particular CMOs and the key challenges associated with the manufacture of biosimilars.
Learn more by downloading the free preview file, or by purchasing the full report below.